摘要
观察肝康Ⅱ号治疗慢性乙型肝炎肝纤维化的临床疗效。76例慢性乙型肝炎肝纤维化患者随机分为两组,治疗组(40例)口服肝康Ⅱ号,对照组(36例)口服复方丹参滴丸,疗程均为3个月。观察两组用药前后肝功能、血清肝纤维化指标及肝组织病理等方面的改变。结果显示治疗组肝功能和血清肝纤维化指标均有明显改善(P< 0．01或P<0．05),也优于对照组(P<0．01或P<0．05)。肝脏组织病理检查显示治疗组炎症活动度减轻,肝纤维化程度明显下降。说明肝康Ⅱ号对慢性乙型肝炎肝纤维化有较好的抗肝纤维化作用。
To baserve the clinical effect of Gankang Ⅱ on treating liver fibrosis caused by chronic hepatitis B. Seventy six patients with chronic hepatitis B were randomly divided into two groups. Forty patients in treatment were treated with Gankang Ⅱ. While thirty six patients in control group were treated with Fufangdanshendiwan. The course of both treatment was 3 months. Before and after treatment, changes of liver function, serum liver fibrosis indexes and liver pathology were observed. The results showed the liver function and serum liver fibrosis indexes in treatment group were improved significantly after treating, and it was better than those in control group （ P 〈 0. 01 or P 〈 0. 05 ）. Pathological examination of liver biopsy showed that inflammatory activity alleviated and the degree of liver fibrosis reduced significantly. Gankang Ⅱ has a definite effect of anti - liver fibrosis.
出处
《临床肝胆病杂志》
CAS
2006年第5期328-329,共2页
Journal of Clinical Hepatology
